UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 85.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 48,981 shares of the company’s stock after acquiring an additional 22,540 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.10% of Spyre Therapeutics worth $1,140,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Huntington National Bank purchased a new stake in Spyre Therapeutics during the fourth quarter worth about $34,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Spyre Therapeutics during the 4th quarter valued at approximately $46,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Spyre Therapeutics during the 4th quarter worth approximately $182,000. Tower Research Capital LLC TRC increased its stake in shares of Spyre Therapeutics by 1,548.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,574 shares of the company’s stock worth $200,000 after purchasing an additional 8,054 shares during the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of Spyre Therapeutics by 38.4% in the 4th quarter. Arizona State Retirement System now owns 10,115 shares of the company’s stock worth $235,000 after purchasing an additional 2,805 shares during the period. 80.39% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on SYRE shares. Wolfe Research initiated coverage on Spyre Therapeutics in a report on Tuesday, March 18th. They set an “outperform” rating and a $27.00 price objective for the company. Leerink Partnrs raised Spyre Therapeutics to a “strong-buy” rating in a research report on Tuesday, April 8th. The Goldman Sachs Group upgraded Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 18th. Leerink Partners started coverage on Spyre Therapeutics in a research note on Tuesday, April 8th. They issued an “outperform” rating and a $45.00 price objective on the stock. Finally, Wedbush reaffirmed an “outperform” rating and set a $65.00 price objective on shares of Spyre Therapeutics in a report on Monday, May 5th. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Spyre Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $53.40.

Spyre Therapeutics Stock Performance

Shares of Spyre Therapeutics stock opened at $17.16 on Tuesday. The stock has a market cap of $1.03 billion, a P/E ratio of -2.30 and a beta of 2.72. The stock’s fifty day moving average is $14.27 and its 200 day moving average is $19.37. Spyre Therapeutics, Inc. has a one year low of $10.91 and a one year high of $40.26.

Spyre Therapeutics (NASDAQ:SYRE) last released its earnings results on Thursday, May 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.02. Analysts predict that Spyre Therapeutics, Inc. will post -4.46 EPS for the current year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).